- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 9, 2024
Data Byte
FDA’s October approvals include the first CLDN18.2 mAb
Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products
BioCentury | May 31, 2023
Deals
May 30 Quick Takes: China deals for C4, Adcendo
Plus: GreenLight accepts a take-private offer, while Atea rejects one; and updates from Amylyx, Lexicon, Pfizer, BMS, Iovance and more
BioCentury | May 4, 2023
Finance
May 4 Quick Takes: Acelyrin’s $540M IPO largest since Sana in ‘21
Plus: Roche launches institute for human models and updates from J&J, HELP and CMS
BioCentury | Aug 8, 2022
Deals
Pfizer promises expanded global reach for sickle cell drug in $5.4B GBT takeout
Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales
BioCentury | Mar 17, 2020
Product Development
March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan
BioCentury | Jul 8, 2019
Clinical News
July 8 Clinical Quick Takes: Hemophilia data from Sangamo-Pfizer, Novo; plus GamaMabs, Xarelto and more
BioCentury | May 19, 2017
Strategy
Full set in hemophilia
How Pfizer’s Sangamo deal fits into its hemophilia and gene therapy strategies
BioCentury | Apr 15, 2017
Product Development
Outside factors
How new hemophilia products could usher in personalized treatment strategies
BioCentury | Mar 25, 2017
Strategy
Mountain climbing
How Novo Nordisk aims to return to higher operating income growth
Items per page:
1 - 10 of 18